drugset / Trial / NCT05985343
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction
RandomizedParallel-groupSingle-blindSupportive care
Summary
The aim of the study is to determine if the usage of sugammadex would reduce the time to return of bowel function when compared to standard of care (neostigmine/glycopyrrolate) when used for neuromuscular blockade reversal in patients with open abdominal wall reconstruction (AWR).
Timeline
- Start
- 2024-01-15
- Primary completion
- 2025-05-30
- Completion
- 2025-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glycopyrrolate | Small molecule | — | — |
| Subject | Neostigmine | Other / unclassified | 0.03 mg/kg | — |
| Subject | Neostigmine | Other / unclassified | 0.07 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Sugammadex | Other / unclassified | 4 mg/kg | Intravenous |